IP Library Granted Patent US 10,870,663
Granted Patent B2
US 10,870,663 · App. 16/897,351 · Granted Dec 22, 2020

Compounds useful in HIV therapy

Inventors: Richard M Dunham (Research Triangle Park, NC); David Margolis (Chapel Hill, NC); Vincent Wing-Fai Tai (Research Triangle Park, NC); Jun Tang (Research Triangle Park, NC)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07D519/00A61P31/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,663
App. No.
16/897,351
Granted
Dec 22, 2020
Kind
B2
Abstract

The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

Claims (13)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A salt according to claim 1 , wherein the salt is present as a hydrochloride salt.

3. The salt according to claim 2 , wherein the hydrochloride salt is a dihydrochloride salt.

4. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. The composition according to claim 4 , wherein said composition is adapted for parenteral administration.

6. A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

8. A compound having the structure:

9. A pharmaceutical composition comprising a compound according to claim 8 , and a pharmaceutically acceptable excipient.

10. The composition according to claim 9 , wherein said composition is adapted for parenteral administration.

11. A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 8 .

12. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 8 .

Assignments (4)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
CHANGE OF ADDRESS Recorded Jun 17, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 071649/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2023
From: DE LA ROSA, MARTHA ALICIA; TAI, VINCENT WING-FAI; TANG, JUN; DUNHAM, RICHARD M.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; VIIV HEALTHCARE COMPANY
Reel/Frame 064350/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2023
From: MARGOLIS, DAVID
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 064350/0747 →
Continuity (3)
Continuation 16621312
Provisional Application 62773563 · Nov 30, 2018
Related Publication 20200299309A1 · Sep 24, 2020